CGON — CG Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1991792 ·
Last close
$71.19
Market Cap
$6.28B
52W High
$77.00
52W Low
$53.21
ADV30
1,179,230
Next earnings
2026-08-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,083,000 | -1,879,000 | -66,389,000 | -60,202,000 | 1,135,262,000 | 33,700,000 | 43,483,000 |
| Dec 2025 | 2,322,000 | -748,000 | -48,700,000 | -41,309,000 | 791,592,000 | 32,490,000 | 38,990,000 |
| Sep 2025 | 1,666,000 | 89,000 | -51,129,000 | -43,808,000 | 729,913,000 | 45,145,000 | 42,270,000 |
| Jun 2025 | 0 | — | -48,741,000 | -41,426,000 | 701,445,000 | 14,624,000 | 31,087,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-132,346,000
Investing CF
$-245,822,000
Financing CF
$153,590,000
CapEx
$-134,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-378,976,000
Inventory
$1,565,000
Receivables
$688,000
ST Investments
$709,665,000
EBIT TTM
$-190,774,000
Pretax Income TTM
$-160,995,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,071,000
EBITDA
$-212,696,992
Free Cash Flow
$-105,890,376
Enterprise Value
$5,210,466,816
Total Cash
$1,076,242,048
Total Debt
$7,575,000
Shares Out
88,202,473
Trailing EPS
$-2.34
Book Value
$12.40
ROE
-20.8%
ROA
-14.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,040,000 | -190,774,000 | -160,995,000 | 791,592,000 | 38,990,000 | — | -132,346,000 |
| Dec 2024 | 1,139,000 | -114,666,000 | -88,039,000 | 754,797,000 | 21,420,000 | — | -78,713,000 |
| Dec 2023 | 204,000 | -55,449,000 | -48,607,000 | 199,301,000 | 14,511,000 | — | -45,679,000 |
| Dec 2022 | 191,000 | -35,246,000 | -35,443,000 | 147,747,000 | 22,570,000 | — | -29,804,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.75
Max Pain — expiry 2026-08-21
max pain strike: $70.00 · spot: $71.19 · call oi: 12,723 · put oi: 2,211
Expected Move to 2026-08-21:
±$14.70
(20.65%) —
implied range
$56.49 –
$85.89
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TWST | Twist Bioscience Corp | $5.70B | $91.55 | — |
| SRRK | Scholar Rock Holding Corp | $5.67B | $47.29 | — |
| IBRX | ImmunityBio, Inc. | $7.51B | $7.17 | — |
| PCVX | Vaxcyte, Inc. | $7.81B | $54.08 | — |
| IMVT | Immunovant, Inc. | $7.93B | $38.62 | — |
News headlines (Yahoo Finance, 1h cache)
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Renewed Pressure on Semiconductor Stocks
2026-07-28 13:00 · Yahoo
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
2026-07-27 22:45 · Yahoo
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
2026-07-16 20:34 · Yahoo
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
2026-07-13 13:03 · Yahoo
Big Insider Buying Puts These 2 Stocks on the Radar
2026-07-05 17:55 · Yahoo
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
2026-06-23 14:31 · Yahoo
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
2026-06-10 07:02 · Yahoo
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
2026-06-07 21:05 · Yahoo
Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?
2026-05-31 21:08 · Yahoo
CG Oncology to Present at Upcoming Investor Conferences in June
2026-05-28 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.